Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07219407 · ClinicalTrials.gov registry record · Phase 2
A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures
A Phase 2 study of Epilepsy and Focal Epilepsy, sponsored by Rapport Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 7
- Study locations
NCT07219407 is a Phase 2 study of Epilepsy and Focal Epilepsy that is actively recruiting participants, run by Rapport Therapeutics. The registered enrollment target is 30 participants, below the 952-participant average among 160 other Epilepsy trials with a reported enrollment target (97% lower). The trial reports 7 study locations across 7 states.
The verdict
NCT07219407, a Phase 2 study of Epilepsy and Focal Epilepsy, is actively recruiting participants, sponsored by Rapport Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 7
- Study locations
Study Summary
This is a clinical research study for an investigational drug called RAP-219 in patients with Refractory Focal Epilepsy. This study is being conducted to determine RAP-219 Long- term safety and open-label antiseizure activity in patients with Refractory Focal Epilepsy.
Conditions Studied
Interventions
- DRUG RAP-219
Study Locations (7)
Idaho
- Consultants in Epilepsy and Neurology, PLLC - Boise
Minnesota
- Mayo Clinic - Rochester
New York
- NYU Langone Comprehensive Epilepsy Center - New York
Ohio
- Cleveland Clinic Foundation - Cleveland
Pennsylvania
- University of Pennsylvania - Department of Neurology - Philadelphia
Tennessee
- Vanderbilt University Medical Center - Nashville
Texas
- Baylor College of Medicine - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-12-15 |
| Est. Completion | 2028-02-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07219407
The ClinicalTrials.gov registry entry for NCT07219407 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 952-participant average among 160 other Epilepsy trials with a reported enrollment target (97% lower). The listed sponsor is Rapport Therapeutics, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with Epilepsy appearing as the primary indexed condition, and to 1 intervention - of which RAP-219 is the first listed.
NCT07219407 reports 7 study locations spanning 7 distinct geographic areas - top geographies include Idaho, Minnesota, New York.
Frequently Asked Questions
What is clinical trial NCT07219407 about?
NCT07219407 is a clinical study titled "A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures". This is a clinical research study for an investigational drug called RAP-219 in patients with Refractory Focal Epilepsy. This study is being conducted to determine RAP-219 Long- term safety and open-label antiseizure activity in patients with Refractory Focal Epilepsy.
What is the current status of trial NCT07219407?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2025-12-15. Estimated completion is 2028-02-03.
What conditions does trial NCT07219407 study?
This clinical trial studies the following conditions: Epilepsy, Focal Epilepsy, Seizure, Focal Seizure, Focal Onset Seizure.
What interventions are being tested in trial NCT07219407?
The interventions under investigation include: RAP-219 (DRUG).
Who is sponsoring clinical trial NCT07219407?
This trial is sponsored by Rapport Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07219407 being conducted?
This trial has 7 study locations across Idaho, Minnesota, New York, Ohio, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Epilepsy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention Study
RECRUITING · Phase 2
-
RNS System LGS Feasibility Study
ACTIVE NOT RECRUITING · Phase 2
-
Study of an External Responsive Neurostimulator System on Epileptiform Activity
COMPLETED · Phase 2
-
Abnormal Ventilatory Response to Carbon Dioxide: a Potential Biomarker for Seizure Induced Respiratory Depression & Modification by SSRI
COMPLETED · Phase 2
-
Hormone Replacement in Menopausal Women With Epilepsy
COMPLETED · Phase 2
-
Pediatric Epilepsy Study in Subjects 1-24 Months
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.